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Pedro Oliveira1*, Leid Zejnilovic1,2, Helena Canhão3 and Eric von Hippel4Abstract: We provide the first empirical exploration of disease-related innovation by patients and their caregivers.
Our aims were to explore to what degree do patients develop innovative solutions; how many of these are unique
developments; and do these solutions have positive perceived impact on the patients’ overall quality of life? In
addition, we explored the factors associated with patient innovation development, and sharing of the solutions that
the patients developed.
Methods: We administered a questionnaire via telephone interviewing to a sample of 500 rare disease patients and
caregivers. The solutions reported were pre-screened by the authors for their fit with the self-developed innovation
aim of the study. All the reported solutions were then validated for their novelty by two medical professionals.
Logistic regression models were used to test the relationships between our key variables, patient innovation and
solution sharing.
Results: 263 (53%) of our survey respondents reported developing and using a solution to improve management
of their diseases. An initial screening removed 81 (16%) solutions for being an obvious misfit to the self-developed
innovation aim of the study. This lowered the sample of potentially innovative solutions to 182 (36%). Assessment
of novelty and usefulness of the solutions, conducted by two medical evaluators, confirmed that 40 solutions (8%)
were indeed novel, while the remaining 142 (28%) were already known to medicine. The likelihood of patient
innovation increased as the education level increased (OR 2, p < 0.05), and as their perception of limitations
imposed by their disease increased (OR 1.3, p < 0.05). 55 individuals diffused their solutions to some degree, with
50 of these sharing via direct diffusion to other patients. There is a positive relationship between the impact of a
solution on the respondents’ overall quality of life and likelihood of solution sharing.
Conclusions: Given that hundreds of millions of people worldwide are afflicted by rare diseases, patient and their
caregivers can be a tremendous source of innovation for many who are similarly afflicted. Our findings suggest that
many patients could be greatly assisted by improved diffusion of known solutions and best practices to and among
patients and their caregivers.
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There are 5000 to 8000 rare diseases which, taken to-
gether, afflict up to 8% of the world’s population [1,2].
Most are genetic and chronic, and many impose signifi-
cant difficulties on the daily lives of both patients and
their caregivers [3]. Patients with rare diseases also tend
to be underserved both clinically and scientifically [4].
Small market size, due to each diseases’ low prevalence,
makes it commercially unattractive for pharmaceutical* Correspondence: poliveira@ucp.pt
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unless otherwise stated.firms and other medical suppliers to invest in developing
new products specifically for rare diseases [5].
High patient need coupled with low commercial activ-
ity in rare disease marketplaces creates both a need and
an incentive for patients and their caregivers to innovate
for themselves to help them with respect to many qual-
ity of life issues. Studies of innovation by citizens show
that useful innovation by patients to serve their own
needs is likely: many citizens have been found to develop
and improve products for their own use in a wide range
of fields, including medical care needs [6-8]. Indeed, in-
dividuals with high and unmet need for a solution often
develop a solution/product for their own use before a. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to the market [9,10].
An increasing stream of literature argues for a more
prominent role of patients and caregivers in healthcare de-
livery [11-14]. However, this literature does not yet con-
sider the innovation capacity of patients and caregivers.
Recent qualitative research has found that patients and
caregivers are not only the drivers of institutional research
[15], they invent a myriad of valuable solutions to improve
their own personal medical situations. These solutions
span from simple tools for everyday use, through discov-
ery of previously unknown therapies, to highly sophisti-
cated solutions. An example of the latter is a textile mesh
support for dilated heart aorta developed by a Marfan syn-
drome patient [16,17]. Emergence of innovation inter-
mediaries in healthcare [18], and initiatives to discover
and share patients’ solutions (like www.patient-innovation.
com) suggest that the awareness of patients’ innovation
capacity is increasing. Still, there is a dearth of quantitative
academic research related to patient innovation.
Patients and their caregivers who develop solutions to
address some of their disease related problems can poten-
tially give valuable contributions to the stock of knowledge
about their diseases and ways to cope with them. The gen-
eral value of these solutions increases if the solutions dif-
fuse. Our objectives in this study are to explore: to what
degree do patients develop innovative solutions; how
many of these are unique developments; do these solu-
tions have positive perceived impact on quality of life; and,
whether the patients share their solutions and how. With
this paper, we aim to provide evidence of the rare diseases
patients’ innovation activity, and propose paths for further
research on this important topic.
Methods
Data collection
We conducted a survey of patients with rare diseases
with the support of an association of mental deficiencies
and rare diseases located in Europe. The association has
about 800 patients registered as its members and runs a
help-line to support patients inquiring about administra-
tive and disease related issues. The association docu-
ments all contacts, and together with the information
on members has records of about 5000 individuals who
had contacted its help-line in the period from 2009 until
the end of 2012. From these 5000, the association’s staff
randomly selected a sample of 1000 individuals for us
to contact.
Four, trained social workers with extensive experience
in working with rare diseases patients within the help-
line, were appointed by the Association to administer
our survey. To familiarize these individuals with the
content of the survey and goals of initial testing and val-
idation of the survey, our research team organized twotraining meetings, and conducted two testing/validation
sessions to adjust the survey to the targeted population
and clarify interpretation. The interviewers contacted in-
dividuals on the association-supplied list in sequence,
continuing until we had obtained completed question-
naires from 500 subjects.
Interviewers began each telephone interview session by
identifying the participating organizations and explaining
the purpose and topic of the survey. They proceeded to
the questionnaire itself only after receiving the subjects’
consent to participate. The interviewers made 546 calls to
the patients from the help-line’s contact list, to gather 506
responses (93% response rate), of which 500 were usable
for further processing. Average call duration was 32 mi-
nutes, with calls taking anywhere from 10 to 90 minutes.
All the information collected by the interviewers and in-
cluded in the dataset for analysis was de-identified. Pa-
tient data was analyzed as a group with no individual
disclosure of classified information according to the
Helsinki Declaration for human studies. Local ethics
committee (Comissão de Ética do Centro Hospitalar
Lisboa Norte” (Ethics Commission of the Center of
Hospitals in the North Lisbon)) gave their approval for
the content of the survey. The data used in this paper,
from the survey and other sources, are described in
Additional file 1: Table S1.
Our survey was partitioned into 7 sections. It con-
tained 67 questions in total. All were grounded in user
innovation literature. In the first section, we identified
the respondents as patients or caregivers, and adapted
the language of the questions that followed accordingly.
We next asked about the limitations imposed by the pa-
tient’s disease upon both patients and caregivers. We
then asked about perceived needs for health-related so-
lutions, and asked whether the patient or a caregiver had
developed a solution that helped them cope with the pa-
tient’s disease. Depending on the answer, respondents
were branched to one of four sections; (2) no solution
developed; (3) equipment or technical aid development
(4) therapy development; or (5) a behavioral change de-
veloped. Respondents with developments were then
asked to describe what they had developed in detail. To
estimate the value provided by their solution, respon-
dents were also asked to estimate their overall quality of
life before using their solution, and after using it. We
used a single-item, 7-point Likert Scale to measure the
quality of life. If the respondent was a caregiver, quality
of life changes for both the caregiver and the patient
were asked about. The 6th section asked questions
about respondent demographics, and the 7th asked
about respondents’ use of the Internet and medical
community memberships.
We applied a two-step procedure for assessing the
novelty of the solutions. In the first step, the authors of
Table 1 Socio-demographic characteristics of the
respondents
Variable N % Mean SD Min Max
Respondent’s Age (years) 45 13 18 84
Disease Duration (years) 12 12 0.2 65
Women 425 85
University Degree 194 39
Employed 255 51
Married 322 64
SD = standard deviation
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to the aim of the study. After the initial screening, as-
sessment of the novelty of all the solutions developed by
the respondents was conducted independently by two
Ph.D. medical professionals, who each had both clinical
and research expertise. These individuals had available
the information about the disease and its duration, the
patients’ gender, and hand-collected descriptions about
each of the 251 diseases identified in the sample. In
addition, two research assistants collected information
about common therapeutic practices for the diseases.
Each clinician-evaluator independently read through the
patient solution descriptions and, based upon their ex-
pert medical knowledge, evaluated whether respondents’
novelty claims were correct, or whether the solution was
already known to them or the medical practice for the
disease. While evaluating they checked the medical lit-
erature and the information collected by the research as-
sistants. The two expert evaluators had very good inter-
rater agreement (kappa = 0.81). Only when both agreed
that a solution was novel did we code the solution as a
patient innovation. If the solution was already known to
medicine, although not to the respondent describing it,
the solution was coded as a redevelopment. Redevelop-
ments are of value to individual patient developers who
obtain the use of a pre-existing solution in this way, but
do not add to the stock of available medical knowledge
– they are not new to the world. We also asked the eval-
uators to assess all the solutions and judge whether in
their opinion the solutions are useful or helpful for the
patients. Together with the evaluators, we established
three criteria to assess the solutions’ usefulness/helpful-
ness: (i) it helps the patients or caregivers in their daily
activities; (ii) it may help in coping with the disease; and
(iii) it is a cost saving alternative to something that
already exists. The evaluators were asked to give one
general assessment of the solutions as useful or not-
useful, based on these three criteria. In addition, the
evaluators indicated which of the solutions they consid-
ered to be dangerous.
Data analysis
In our statistical analyzes, we built and tested two multi-
variate discrete choice models to explore what motivated
respondents to innovate in the community of rare dis-
eases patients and what drove them to share their solu-
tions. In the first case, our dependent variable was the
validated innovation. We included the following inde-
pendent variables: 1) socio-demographic variables (as
shown in Table 1); 2) disease prevalence, obtained from
external databases (OrphaNet, Medline, NIH, etc.) and
categorized into 5 categories: higher than 1/1000; 1 to
9/10,000; 1 to 9/100,000; 1 to 9 in 1,000,000; or lower
than 1/1,000,000; this variable was inversely coded – thelower the prevalence, the higher is the category; it allowed
us to test whether lower prevalence implies higher need
for solutions and higher likelihood of patient innovation;
3) disease burden: we asked the respondents to tell us to
what extent does their disease impose limitations on their
life, measured on a 5-point scale, from 1 – the disease im-
poses no limitations on my life, to 5 – the disease imposes
extreme limitations on my life; 4) medical patient commu-
nity membership; it indicates whether the respondent (or
the patient if appropriate) belong to any formal group/as-
sociation of patients with the same disease as they do.
Also, to test for non-linearity of the effects of the respon-
dents’ age and their disease duration on innovation, we in-
cluded squared terms of these two variables.
We built another model to test the likelihood of informa-
tion disclosure. Beside the variables from the first model,
we added one variable to this model: the difference in the
overall quality of life between the reported values for the pe-
riods before the innovation and after the respondent used
the solution; the quality of life for the two time periods was
measured on a 7-point scale, from 1 – extremely low, to
7 – excellent. We conducted the analysis using two data
samples: 1) full-sample with 263 reported solutions; and 2)
restricted sample with 182 solutions that passed the pre-
screening. The rationale for including the both samples is
the following: for studying the solution sharing activity,
what matters is whether the respondents believe that they
have developed something; to check the robustness of the
results, we included the analysis using the restricted sample.
We presented our results as raw coefficients in the ta-
bles, together with robust standard errors. Continuous
variables are expressed as mean and standard deviation
and discrete variables as absolute frequency. In the text,
we report odds ratios and 95% confidence intervals
as measures of effect. Significant p-values were set
to <0.05. Stata 13 software was used for data analysis.
Results
Population included in our study
Respondents’ socio-demographic characteristics are de-
scribed in Table 1.
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our sample were caregivers (59%), and 85% of the re-
spondents were women. Women also constituted 65% of
all the patients in our sample.
The average age of patients in our sample was 33 years,
with a standard deviation of 22 years, while the average
age of the respondents was 45 years with a standard de-
viation of 13 years. 65% of the respondents were be-
tween 18 and 45 years old. The disease duration was
12 years with a standard deviation of 12 years. One-third
of the respondents held university degrees, 51% were
employed, and 64% were married or in de facto unions.
The extent and types of patient-developed innovations
263 (53%) of our 500 respondents reported having devel-
oped a solution they regarded as novel to assist them
in managing their disease. The initial screening removed
81 solutions, leaving 182 (36% of 500) potentially novel
solutions. Further evaluation by the expert medical
evaluators suggested that the solutions of 8% of our
respondents were also evaluated as novel – “new to
the world” – by our expert medical evaluators. The
remaining claimed innovations that passed the initial
filtering were judged by our expert evaluators to be
redevelopments – novel to the patient developer, but
already known to medicine. In the following tables
we use the restricted sample of 182 reported as novel
solutions that passed the initial screening, unless other-
wise indicated.
Almost all the reported solutions were also judged by
the experts to be relatively safe: out of 182, only 4 (2%)
of the patients’ developments were judged to be poten-
tially detrimental to patients’ health by the evaluators.
73 (40%) of the patients’ developments were judged to
be useful, regardless of their novelty. As can be seen in
Table 2, we divided patient developments into two
categories, products and services. Developments were
coded as products if there was a description of a medical
equipment or an assistive product, as defined in Article
2.3. of ISO 9999:2011 [19]: “any product (including de-
vices, equipment, instruments and software), especially
produced or generally available, used by or for persons
with disability for participation; to protect, support, train,
measure or substitute for body functions/structures andTable 2 Type, novelty, and usefulness of reported solutions
Novelty
Novel to the patient
(% of 142)
Novel to the
world (% of 40)
T
(
Products 4 (3%) 15 (37%) 1
Services 138 (97%) 25 (63%) 1
Total (% of 182) 142 (78%) 40 (22%) 1
Note: Novelty and usefulness are judged by two medical professionals, kappa = 0.8.activities; or to prevent impairments, activity limitations
or participation restrictions.” Developments were de-
fined as services in other cases, where we found a de-
scription of an activity or a plan of activities related to
treatments or changes in strategies or behavior related
to the disease. 90% of the reported solutions were cate-
gorized as services – very few were product innovations.
Examples of the solutions
Most of the solutions in our sample are technically very
simple, but nonetheless offer great value to patients. Con-
sider the case of a mother who takes care of her son, an
Angelman syndrome patient. Angelman syndrome in-
volves ataxia, inability to walk, move or balance well. The
mother experimented with many strategies, recommended
by the doctors, therapists, or found elsewhere, but ob-
tained little gain for her child. By chance, at a neighbor’s
child’s birthday party, she noticed her son excitedly jump-
ing for strings to catch a floating helium-filled balloon.
This gave her an idea and she experimented at home by
filling a room with floating balloons. She found her child
began jumping and reaching for the balloons for extended
periods of time, amused by the challenge. The mother also
added bands to support the knees and keep the child in an
upright position. The result was significant improvement
in her child’s physical abilities. Other parents to whom she
described the solution also tried the balloons strategy and
had positive results. This was valued as a novel solution
by the medical evaluators.
Consider now a mother of a kid with cerebral palsy.
This disease, among other manifestations, makes the
kid to hyper salivate. Besides being a discomfort and a
potential source of disease, the hyper salivation is also a
cause for social exclusion. The medical solution for this
problem - removing the salivary glands - is considered
by this mother as too drastic and with very limited bene-
fits. Instead, she tried solving the problem by consider-
ing strategies that allow her son socializing more easily
with other people. She developed “The Cute Turtle
Collar”, a kind of a turtle collar piece made of a material
that absorbs well the slobber, and is both stylish and
suitable to use in all weather conditions.
Several of the reported solutions included descriptions
of intensive physical activity, which, according to theUsefulness/Helpfulness
otal
% of 182)
Dangerous
(% of 4)
Not useful/helpful
(% of 105)
Useful
(% of 73)
9 (10%) 0 4 (4%) 15 (21%)
63 (90%) 4 (100%) 101 (96%) 58 (79%)
82 (100%) 4 (2%) 105 (58%) 73 (40%)
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overall quality of life. Daily practice of martial arts, Muay
Thai and kick-boxing up to 5 hours a day, is an uncom-
mon choice for a Trombocitopenic purpura patient.
The patient opted for this sort of exercising contrary to
the advice of health professionals not to engage in phys-
ical activities that could hurt the body. The respondent
reported significant decrease in frequency of hemor-
rhages, which she associates with the intensive practice
of martial arts.
Another case from our sample, that also involves in-
tense physical activity, is of a boy afflicted by Charcot-
Marie-Tooth disease. This disease makes the patients
progressively lose muscle tissue and touch sensation,
and often the first visible symptoms of the disease ap-
pear in legs and hands. The boy’s daily practice of play-
ing piano has slowed down the disease’s development in
hands and masked some of the symptoms, which made
the diagnostic process harder. He continued playing the
piano, and the hands remained fully functional, with lit-
tle or no sign of the disease, while he may need a foot
surgery to maintain the desired level of functionality.
Benefits of physical exercise are well-known, but, in this
case, the intensity of the exercise may have changed the
development of the disease. This information may be
useful for medical professionals in establishing a correct
diagnosis for similar cases earlier, and also as a strategy
to be considered by other patients and caregivers.
The vast majority of the innovations in our sample
have been developed to increase the patients’ autonomy.
For example, a patient with Myasthenia gravis, an auto-
immune neuromuscular junction disorder, reported
designing several products custom-built according to
her specifications. She described a design of one of the
tools – a metal two-hook button aid that helps her but-
ton pants without assistance of others. Although an on-
line search quickly reveals variety of button hooks,
patients, as is the case described, often experiment with
the design to make the one that better fit their specific
condition and needs. Other solutions reported involved
experimentation with the design of elements commonly
found in any household; for example, optimization of the
height and width of stairs to improve mobility, or design
of tables and chairs with added features to increase safety
of hyperactive children with cognitive limitations.
The impact of the solutions
The majority of the respondents who reported a solution
described substantial improvements in their overall qual-
ity of life as a result of using their solutions. For solu-
tions that were new to the patient but not new to the
world, the mean improvement in quality of life of the
patients was 1.6 on a seven-point Likert scale. For solu-
tions that were new to the world, the improvement inquality of life of the patients was 2 points on a seven-
point Likert scale. Caregivers reported mean improve-
ments in the quality of their lives of 1.4 for non-novel
and 1.9 for novel solutions (Table 3).
Quality of life improvements resulting from using the
innovations were significant (p < 0.001, two-tailed t-test).
The difference in quality of life improvements was not
significantly different (p < 0.21, two-tailed t-test) in the
case of innovations that were new to the individual pa-
tient/respondent compared to new to the world.
We matched the perceptions of the solutions’ useful-
ness, as seen by medical experts, with the patients’ per-
ceptions of their overall quality of life improvements due
to use of their solutions. The experts judged as not help-
ful 68 (59%) of 115 solutions that the patients reported
as beneficial for their quality of life. Also, the experts
judged as useful 23 (44%) of 52 solutions for which pa-
tients reported no improvements (Table 4).
The extent and type of solution diffusion
In our sample of respondents, we found that 32% (84) of
all the patients and caregivers who reported solutions
also reported investing efforts to share their solutions
with others. After the initial screening, of the remaining
182 solutions (restricted sample), 55 (30%) respondents
reported sharing their solutions with others (Table 5).
We asked about seven types of diffusion effort that
they might have undertaken. On average, they reported
engaging in 1.5 of these diffusion activities in the re-
stricted sample. 39 (71%) individuals reported only en-
gaging in one of the seven possible diffusion activities.
Diffusion effort was significantly higher (p < 0.05, two-
tailed t-test) in the case of innovations that were new to
the world than in the case of redevelopments that were
only new to the individual patient/respondent, but only
in the non-restricted sample. In the restricted sample
there was no statistically significant difference between
the two groups.
Considering the full-sample, the most common mode
of sharing was patient-to-patient, reported by 74 individ-
uals – 88% of those who shared a solution. Interestingly,
only 5 individuals - 6% of the respondents who shared
solutions – shared their solutions with their doctors.
Sharing with commercial firms occurred in 3 cases. In
four cases, patients or caregivers spent time or money to
help diffuse their innovations. In three of these cases,
the developers also reported making a manual or docu-
mentation to help others use their solutions.
What influences patient innovation and solution sharing
We next assess factors that are associated with patients’ like-
lihood of developing and sharing their novel developments.
Two factors may help predicting patient’s likelihood
to innovate (model 1, Table 6). The coefficient next to
Table 3 Perceived difference in overall quality of life after using the solutions
New to the respondent New to the world
Quality of life difference Quality of life difference
Patients Caregivers Patients Caregivers
Products Nr. of cases 4 1 15 9
Mean (SD) 2.2 (2.2) 0 (0) 2.2 (1.5) 1.7 (1.4)
Services Nr. of cases 132 62 24 17
Mean (SD) 1.6 (1.5) 1.5 (1.5) 1.8 (1.4) 2 (1.7)
Total Nr. of cases 136 63 39 26
Mean (SD) 1.6 (1.5) 1.4 (1.5) 2 (1.4) 1.9 (1.6)
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is positive and statistically significant (p < 0.05): a one-
point increase in perceived limitations imposed by the
disease increases odds of patient innovating by a factor
of 1.3 (95% CI: 1.0 - 1.7), everything else held constant
(model 1). Also, having a university degree increases
likelihood of patient innovation, with an increase of odds
of patient innovating by a factor of 2 (95% CI: 1.0 – 3.0;
p < 0.05) (model 1).
In models 2 and 3 we explored factors significantly as-
sociated with innovation sharing. Model 2 included the
full sample of 263 reported solutions, while model 3 in-
cluded only 182 reported solutions that passed the initial
screening. The strongest predictor of information shar-
ing was the observed difference in the respondents’ over-
all quality of life before and after using a solution, in
both models 2 and 3. A one-point increase in the per-
ceived difference increased odds of sharing the solution
by a factor of 1.7 (95% CI: 1.4 - 2.1), everything else held
constant (p < 0.01) (model 2). The effect was robust to
the change in the sample size in both the magnitude and
the statistical significance. Also, we found an inverted U
relationship between the age and the likelihood of shar-
ing a solution - the effect of age on the predicted prob-
ability becomes negative after the age of 55 (p < 0.05)
(model 2). The non-linear effect of age on the solution
sharing did not maintain the statistical significance level
in the non-restricted sample, although both the sign and
the coefficient remained the same (model 3). Also, a major
difference between models 2 and 3 is that duration of aTable 4 Perceptions of the solutions’ usefulness by patients a
Reported (b
No change
Medical professionals’ assessments Dangerous 1
Not helpful/useful 28
Helpful/Useful 23
Total (% of 170) 52 (31%)
Note: *the difference in the number of dangerous solutions in Tables 2 and 4 is duedisease has positive and non-linear relationship with the
solution sharing in model 3, which was not the case in
model 2. The instability of the results for the age and dis-
ease duration with respect to the solution sharing suggests
that further exploration is needed to clarify these effects.
Discussion
Our first-of-type study has found that 36% of our sample
of rare disease patients and/or their non-professional
caregivers have self-developed improvements to the
management of their diseases and that use of these, sig-
nificantly improved their quality of life. Our expert clin-
ical evaluators determined that 40 (22%) of these 182
claimed improvements were new-to-the-world. The rest
were already known to medicine, although not to the pa-
tient or caregivers who redeveloped them.
We suggest that our results have significant implica-
tions for all stakeholders in the health care delivery
process related to rare diseases. An estimated 6% to 8%
of the world’s population – hundreds of millions of
people - are afflicted by rare diseases. It is known that
commercial innovation efforts on these patients’ behalf
are negatively affected by small market sizes. Our finding
that 8% of rare disease patients and/or their non-
professional caregivers have developed valuable, new to
the world innovations to improve their own care sug-
gests that a massive, non-commercial source of medical
innovations exists. It is today largely hidden due to a
lack of diffusion efforts by innovating patients, but ef-
forts could be made to change this situation.nd medical professionals
y respondents) improvements in overall quality of life (QoL)
in QoL QoL improved Total (% of 167)
2 3 (2%)
68 96 (57%)
45 68 (41%)
115 (69%) 167* (100%)
to missing experts-patients pairs of usefulness-QoL impact estimates.
Table 5 The patients’ solution sharing activities
Non-restricted sample (n = 263) Restricted sample (n = 182)
Solution sharing activity New to the
world
New to the
respondents
New to the
world
New to the
respondents
(n = 19) (n = 65) (n = 19) (n = 36)
Shown it to other patients 89% 88% 89% 92%
Shown it to medical professionals 5% 6% 5% 2%
Shared the info on a website/blog/social network 37% 22% 37% 28%
Shared it through media 16% 5% 16% 8%
Shown it to commercial entities 11% 2% 10% 3%
Spent time and/or money to help others (people, companies) use the solution 11% 3% 10% 5%
Made a manual or documentation that helps using the solution 5% 3% 5% 5%
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the limitations caused by an illness, and also education
level and likelihood of innovation. Both findings are in line
with findings from other studies of innovation patterns
among individual citizens [6,7,20]. We also found that the
extent of improvement of patient quality of life from their
developments is significantly positively associated with
efforts to diffuse their innovations to others. Our data un-
covered a potential principal-agent problem: patients sys-
tematically valuing different innovations than doctors do,
as suggested by the observed differences between patientTable 6 Logit models of likelihood of patient innovation and
(1)
Patie
Disease prevalence 0.15
Disease burden 0.27*
Respondent’s Age 0.13
Respondent’s Age squared −0.00
Disease Duration 0.02
Disease Duration squared −0.00
Gender −0.51
Academic Degree 0.68*
Employment status −0.05
Marital status 0.66
Medical patient community membership 0.39
Improvement in overall quality of life (before-after solution use)
Constant −7.26
Observations 485
Chi2 28.8
McFaden’s pseudo R2 0.08
c-statistics 0.72
Raw coefficients shown; Robust standard errors in parentheses.
*** p < 0.01, ** p < 0.05, * p < 0.1.and clinician evaluations of usefulness (Table 4). In further
work, we suggest that the sources of this difference should
be explored. It is possible, we think, that clinicians assess
the usefulness of innovations primarily in terms of
whether they affect the clinical course of a disease in
beneficial ways. In contrast patients may greatly value in-
novations that may have no impact on the course of their
disease, but that improve their comfort or other aspects of
their quality of life while living with their disease.
Recall that we found that most patient improvement
development efforts were devoted to re-inventing knownsolution sharing
(2) (3)
Non-restricted sample Restricted sample
nt innovation Solution sharing Solution sharing
(0.15) −0.13 (0.16) −0.11 (0.20)
* (0.13) 0.12 (0.14) 0.09 (0.19)
(0.09) 0.25** (0.1) 0.21** (0.11)
2* (0.0) −0.002** (0.0) −0.002* (0.001)
(0.05) −0.07* (0.04) −0.13*** (0.05)
1 (0.0) 0.002* (0.0) 0.002*** (0.001)
(0.42) −0.25 (0.49) −0.29 (0.55)
* (0.3) 0.33 (0.27) 0.37 (0.30)
(0.38) −0.13 (0.36) 0.41 (0.44)
(0.4) −0.01 (0.36) −0.25 (0.45)
(0.43) 0.29 (0.44) 0.30 (0.51)
0.52*** (0.11) 0.55*** (0.15)
*** (2.2) −7.58*** (2.4) −7.53*** (2.54)
231 159
39.1 27.3
0.16 0.18
0.77 0.77
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the solutions patients and caregivers developed were
judged new to the world by our expert clinician raters.
This suggests that information on known solutions, as
well as novel ones, is today poorly diffused, and/or that
information provided by clinicians is poorly absorbed
by many patients. The duration of typical medical
appointments are quite limited, and our finding may
be due to this. A possibly related finding is that only
6% of patients reported describing their innovations to
their clinicians.
Direct patient-to-patient information sharing was the
most common mode of innovation diffusion and was
reported by 88% of those who shared solutions. The
second most common mode of sharing was via blogs/
websites/social networks, reported by 25% of those who
shared solutions. Rare disease patients and caregivers are
known to actively use the Internet and social networks
to find and provide help and connect with others pa-
tients and caregivers [21,22]. As 85% of the respondents
in our sample use the Internet, and of these 71% use so-
cial networks, the reported level of solution sharing over
the Internet appears low. Non-sharing of potentially use-
ful solutions developed by individual citizens has been
identified as a market failure in the user innovation lit-
erature [23]. Future research should explore diffusion
incentives and effective channels for diffusion, taking
into consideration that different age groups may have
different requirements and behavioral patterns.
While our sample offers technically simple solutions,
patient-developed solutions can also be technically very
advanced. As illustration, consider the innovation (not
found in this study sample) developed by a hydraulics
engineer with Marfan syndrome. This individual had an
aortic root aneurysm. Drawing upon his hydraulics en-
gineering background, he developed a personalized ex-
ternal aortic support made from mesh to prevent a
progressively enlarging aorta from prematurely ending
his life [16,24]. More precisely, the patient assembled a
medical and technical team and raised research and de-
velopment money to further implement and diffuse his
innovation. Upon development, his surgeon successfully
installed the aortic support, and the clinical advantage
was clear. To date, the novel treatment has been suc-
cessfully applied to more than 40 patients in the period
from 2004 to 2014 [25].
Given the novelty and medical value of some patient-
developed innovations, as documented in this and other
studies, we suggest that further research on this topic
should be conducted. It would also be useful, we sug-
gest, to develop and experiment with systems to collect
and medically evaluate novel solutions developed by pa-
tients, to identify those worthy of further testing, im-
provement, and diffusion.Study limitations
This study into innovation development by patients and
caregivers has several limitations. First, our sample of
patients and caregivers are retrieved from a population
of those who have already reached out towards the rare
disease association for help via a helpline. These individ-
uals may be more or less likely to innovate than those
who did not make contact. Also, our respondents are
dominantly women, indicating that female patients or
caregivers are more likely to reach out for help through
this particular patient association. This creates a modest
conservative bias in our findings regarding innovation
levels among patients and caregivers.
Second, telephone interviews rather than site visits are
likely to understate the level of patient and caregiver
innovations that actually exist. Individuals often do not
recognize their activities as innovative, or do not report
novel developments they make. This limitation makes
the observed frequency of patient innovation a lower
boundary for the observed population.
Third, self-assessment of satisfaction with a self-
developed solution is known to be inflated by the pride
individuals take in their self-developed solutions [26].
In addition, our quality of life measure is a single item
scale that makes it open to individual interpretation
and limits the ability to compare it across different in-
dividuals. This item does capture how people feel about
their solutions, but caution is needed in interpreting
the results.
Conclusions
We found that 36% of our sample of rare disease pa-
tients and/or their non-professional caregivers had
developed improvements to the management of their
diseases that significantly improved their quality of life.
Our expert clinical evaluators determined that 22% of
these claimed improvements were new-to-the-world,
and that the rest were already known to medicine, even
if not to the patient or caregivers who redeveloped them.
If further research finds that similar frequencies hold
for the broader population, the estimated 6% to 8% of
the world’s population afflicted by rare diseases may col-
lectively offer a tremendous source of information on
how to improve patient medical care. Their contribu-
tions may complement the efforts by policy makers, re-
search entities, and producers, to help improve the
difficult situation of rare disease patients, whose needs
for innovations are often underserved.
It is important to continue investigating how rare dis-
ease patients and caregivers can be helped in their
innovation activity, how innovations can be profession-
ally assessed, and how patient-developed innovations de-
termined to be of general value can be diffused for
broader long-term public health benefits.
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